Abstract

PurposeTo evaluate the importance of morphology in quantifying expression after in vivo gene transfer and to compare gene expression after intra-arterial (IA) and intra-tumoral (IT) delivery of adenovirus expressing a SSTR2-based reporter gene in a large animal tumor model.Materials and MethodsTumor directed IA or IT delivery of adenovirus containing a human somatostatin receptor type 2A (Ad-CMV-HA-SSTR2A) gene chimera or control adenovirus (Ad-CMV-GFP) was performed in VX2 tumors growing in both rabbit thighs. Three days later, 111In-octreotide was administered intravenously after CT imaging using a clinical scanner. 111In-octreotide uptake in tumors was evaluated the following day using a clinical gamma-camera. Gene expression was normalized to tumor weight with and without necrosis. This procedure was repeated on nine additional rabbits to investigate longitudinal gene expression both 5 days and 2 weeks after adenovirus delivery. CT images were used to evaluate tumor morphology and excised tissue samples were analyzed to determine 111In-octreotide biodistribution ex vivo.ResultsVX2 tumors infected with Ad-CMV-HA-SSTR2 had greater 111In-octreotide uptake than with control virus (P<0.05). Intra-arterial and intra-tumoral routes resulted in similar levels of gene expression. Longitudinally, expression appeared to wane at 2 weeks versus 5 days after delivery. Areas of necrosis did not demonstrate significant uptake ex vivo. Morphology identified areas of necrosis on contrast enhanced CT and upon excluding necrosis, in vivo biodistribution analysis resulted in greater percent injected dose per gram (P<0.01) and corresponded better with ex vivo biodistribution(r = 0.72, P<0.01, Coefficient of the x-variable = .72) at 2 weeks than without excluding necrosis (P<0.01).ConclusionTumor specificity and high transgene expression can be achieved in tumors via both tumor directed intra-arterial and intra-tumoral delivery in a large animal tumor model. Using clinical machines, morphologic imaging contributes to functional imaging for quantifying SSTR2-based reporter expression in vivo.

Highlights

  • Gene therapy can be defined as the introduction of genetic material into cells for a therapeutic purpose [1]

  • VX2 tumors infected with Ad-CMV-HA-somatostatin receptor type 2 (SSTR2) had greater 111In-octreotide uptake than with control virus (P,0.05)

  • Morphology identified areas of necrosis on contrast enhanced CT and upon excluding necrosis, in vivo biodistribution analysis resulted in greater percent injected dose per gram (P,0.01) and corresponded better with ex vivo biodistribution(r = 0.72, P,0.01, Coefficient of the x-variable = .72) at 2 weeks than without excluding necrosis (P,0.01)

Read more

Summary

Introduction

Gene therapy can be defined as the introduction of genetic material into cells for a therapeutic purpose [1]. In the clinic, evaluating success of gene transfer is primarily limited to analyses of biopsy samples, yet the information collected from this approach is restricted to a few cubic millimeters of biopsy material As a result, this method provides limited assessment of in vivo gene delivery, is prone to sampling error, has associated morbidity and mortality, and can have problems with patient compliance especially when repeated evaluation is needed. Instead, monitoring of exogenous gene expression should be noninvasive and repeatable over time in the same patient This would inform regarding the location, magnitude, and kinetics of gene expression, and, could prove instrumental towards the IA and IT administration of Ad-CMV-HA-SSTR2, and (b) infected in vivo by IA infusion of Ad-CMV-HA-SSTR2 and by IT injection of control Ad-CMV-GFP (B = bladder, S = source of 111In for positioning). No difference was seen between the IA and IT groups. (d) Contrast enhanced CT showing the small amount of necrosis within the tumors

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call